Novo Nordisk A/S - Share repurchase programme

Udgivet den 19-10-2020  |  kl. 11:23  |  

Novo Nordisk A/S - Share repurchase programme

Bagsværd, Denmark, 19 October 2020 - On 6 August 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the Safe Harbour Rules). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.

Under the programme initiated 6 August 2020, Novo Nordisk will repurchase B shares for an amount up to DKK 2.8 billion in the period from 6 August 2020 to 28 October 2020.

Since the announcement as of 12 October 2020, the following transactions have been made:

  Number of
B shares
Average
purchase price
Transaction
value, DKK
Accumulated, last announcement 5,174,491   2,198,109,903
12 October 2020 105,000 460.04 48,304,447
13 October 2020 105,000 465.05 48,830,248
14 October 2020 105,000 459.62 48,259,589
15 October 2020 105,000 450.54 47,306,483
16 October 2020 105,000 449.99 47,249,259
Accumulated under the programme 5,699,491   2,438,059,929

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 25,747,394 B shares of DKK 0.20 as treasury shares, corresponding to 1.1% of the share capital. The total amount of A and B shares in the company is 2,350,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 5 February 2020. As of 16 October 2020, Novo Nordisk has since 5 February 2020 repurchased a total of 25,758,670 B shares at an average share price of DKK 426.61 per B share equal to a transaction value of DKK 10,988,847,660.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Media:    
Anne Margrethe Hauge +45 4442 3450 amhg@novonordisk.com
Ken Inchausti (US) +1 609 240 9429 kiau@novonordisk.com
     
Investors:    
Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com
Valdemar Borum Svarrer +45 3079 0301 jvls@novonordisk.com
Ann Søndermølle Rendbæk +45 3075 2253 arnd@novonordisk.com
Mark Joseph Root +45 3079 4211 mjhr@novonordisk.com
Kristoffer Due Berg (US) +1 609 235 2989 krdb@novonordisk.com

Company announcement no. 60 / 2020

 

Attachment

CA201019_Safe_Harbour

\Hugin

Udgivet af: NPinvestordk

Seneste nyheder

14:03 Økonomer: Inflationen går den rigtige vej - men Federal Reserve kan ikke ånde lettet op
13:37 Amerikansk inflation går den rigtige vej: Aftager mere end ventet i februar
13:19 USA/tendens: Udsigt til pæne plusser men inflationstal lurer
12:52 Trump indstiller Michelle Bowman som næstformand for Federal Reserves styrelsesråd
12:30 Tidligere Mærsk-topchef overtager formandsposten i Lundbeckfonden
12:12 Europa/aktier: Mulig våbenhvile løfter markeder men sænker våbenaktier
11:52 Obligationer/middag: Renten kravler svagt op før vigtig inflationsrapport
11:42 Puma styrtdykker efter dyster prognose
11:37 Aktier/middag: Zealand brager i vejret på bekostning af Novo efter milliardaftale
10:56 DFDS: Både fragtmængder og passagertal faldt i februar
09:52 Novo-aktien halveret siden toppen: Farvel til 2300 mia. kr. i markedsværdi
09:30 Novo-aktien halveret siden toppen: Farvel til 2300 mia. kr. i markedsværdi
09:17 Aktier/åbning: Zealand tager gigantisk kurshop på milliardaftale
08:54 Obligationer/åbning: Flad renteudvikling før vigtig inflationsrapport
08:46 Zealands aktiekurs kan stige mere end 30 pct. spår Jefferies
08:43 Zealand Pharma har stor tiltro til kombination mellem kronjuvel og mulig "best in class"-molekyle
08:29 Råvarer: Svagere dollar sender oliepriserne i opadgående retning
08:22 Aktier/tendens: Zealand har udsigt til topplacering i ventet grønt marked
08:17 Zealand Pharma har fundet en partner til Petrelintid: Topchef ser enormt potentiale i overskudsdeling
08:00 Tysk våbenproducent skruer lidt ned for salgsvæksten i år efter rekord i 2024